Pharmidex are proud to be part of the recent publication on African Trypanosomiasis in Journal of Antimicrobial Agents

July 19, 2017

Pharmidex team are proud to present it's latest involvement on the recent publication on African Typanosomiasis

Pharmidex are proud to be part of the recent publication on African Trypanosomiasis in Journal of Antimicrobial Agents

The Pharmidex team are proud to present it's latest involvement on the recent publication on African Typanosomiasis which was published in the International journal of antimicrobial agents. Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis - International Journal of Antimicrobial Agents Human African trypanosomiasis (HAT) is a neglected tropical disease, with a population of 70 million at risk. Current treatment options are limited.

In the search for new therapeutics, the repurposing of the broad-spectrum antiprotozoal drug fexinidazole has completed Phase III trials with the anticipation that it will be the first oral treatment for HAT.

For more information please see - https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents

< Older Post

Newer Post >

🌟 Pharmidex is proud to sponsor CamMedChem’25! 🌟

September 12, 2025

We’re delighted to announce that Pharmidex will be an official sponsor of CamMedChem’25 , the renowned meeting organized by the Royal Society of Chemistry’s Biomolecular Chemistry Special Interest Group This year’s theme promises cutting-edge discussions in medicinal chemistry, biomolecular interactions and the latest trends in small molecule and chemical biology research. We’re honoured to support such a pivotal forum for scientists, drug discovery experts and academic innovators to exchange ideas, foster collaborations, and advance therapeutic discovery. 👉 We look forward to: Learning from the powerful scientific insights shared at the meeting Exploring new partnerships that further the translation of biomolecular science into impactful therapies We can’t wait to see you in Cambridge for CamMedChem’25!

Pharmidex Histology Services: Precision You Can Trust

September 8, 2025

At Pharmidex , we deliver comprehensive histology solutions designed to support preclinical and clinical research with accuracy and reliability. 🔬 From sample to slide, our services include: tissue processing, embedding, microtomy, routine and special staining, digital imaging and slide scanning all underpinned by rigorous quality control and expert scientific oversight. With specialist capabilities and high-throughput workflows, we help researchers generate high-quality, reproducible data across toxicology, oncology, CNS and beyond. 👉 Learn more: pharmidex.com/histology

🔬 Expanding our integrated capabilities in autoimmune research

September 3, 2025

At Pharmidex , we are proud to offer a comprehensive preclinical platform for autoimmune disease research. Using in vivo EAE models, we combine: ✔️ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression ✔️ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs ✔️ Pharmacological intervention studies, including established treatments such as Fingolimod for validation This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation. By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects. 👉 Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.